<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311700</url>
  </required_header>
  <id_info>
    <org_study_id>METOCARD-CNIC</org_study_id>
    <secondary_id>CNIC translational Grant 2009</secondary_id>
    <secondary_id>2010-019939-35</secondary_id>
    <secondary_id>Ministerio de Sanidad</secondary_id>
    <nct_id>NCT01311700</nct_id>
  </id_info>
  <brief_title>Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial.</brief_title>
  <acronym>METOCARD-CNIC</acronym>
  <official_title>Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The ME&quot;Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion&quot; (METOCARD-CNIC): A Randomized, Controlled Parallel-group, Observer-blinded Clinical Trial of Early Pre-reperfusion Metoprolol Administration in ST-segment Elevation Myocardial infarctionTOCARD-CNIC Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Sanidad, Servicios Sociales e Igualdad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación Mutua Madrileña</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether early pre-reperfusion metoprolol administration
      in patients suffering and acute myocardial infarction might reduce the size of myocardial
      necrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute myocardial infarction (AMI) is a chief cause of death worldwide. The best strategy to
      limit myocardial damage is to perform an early coronary reperfusion. However, despite
      reperfusion, the size of infarctions is many times large. Infarct size has been recently
      shown to be a strong predictor of future cardiovascular events and mortality. Therefore
      interventions aimed at reducing infarct size are the matter of intense research; but despite
      great efforts, no therapy has been shown to consistently limit infarct size.

      ß-blockers are a class of drugs that have been used to treat cardiovascular conditions for
      several decades. β-blockers reduce mortality when administered after an AMI, and are a class
      IA indication in this context. What remains unclear is what timing and route of β-blocker
      administration gives the maximum cardioprotective effect. In particular, whether early
      β-blocker administration is able to reduce infarct size is a subject of debate. Recent
      experimental data suggest that the β1 selective blocker metoprolol is able to limit the area
      of necrosis only when administered before reperfusion.

      The objective of this trial is to determine whether the administration of intravenous
      pre-reperfusion metoprolol might reduce infarct size.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size evaluated primarily by area of delayed enhancement on cardiac magnetic resonance imaging.</measure>
    <time_frame>5-7 days after reperfusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size evaluated primarily by the area under the curve of CK, CK-MB and troponin release over the first 72 hours of reperfusion.</measure>
    <time_frame>over the first 72 hours of reperfusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size evaluated by area of delayed enhancement on cardiac magnetic resonance imaging.</measure>
    <time_frame>at month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size evaluated by area of delayed enhancement on cardiac magnetic resonance imaging in patients with coronary TIMI flow 0-1 of culprit coronary artery.</measure>
    <time_frame>5-7 days after reperfusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent salvaged myocardium evaluated by cardiac magnetic resonance imaging.</measure>
    <time_frame>5-7 days after reperfusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery of myocardial contraction assessed by magnetic resonance imaging and echocardiography.</measure>
    <time_frame>at month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial perfusion evaluated by magnetic resonance imaging.</measure>
    <time_frame>5-7 days post-reperfusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death, malignant ventricular arrhythmias, reinfarction or admission due to heart failure</measure>
    <time_frame>hospital discharge, 1, 6 and 12 months post-reperfusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events (death, malignant ventricular arrhythmias, AV block, cardiogenic shock, reinfarction).</measure>
    <time_frame>within first 24 hr post-reperfusion.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Early metoprolol initiation strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed metoprolol initiation strategy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injectable (i.v.) metoprolol tartrate (up to 15 mg).</intervention_name>
    <description>Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).
Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.
Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.
Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion.</description>
    <arm_group_label>Early metoprolol initiation strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed* acute anterior wall myocardial infarction (ST segment elevation ≥ 2mm in ≥
             2 contiguous leads [one of which should be V2, V3, or V4]).

          2. Killip class I or II on diagnosis.

               -  Cases of non-confirmed infarction by enzymatic release (above 2 standard
                  deviations from upper limit of CK and Troponin) are excluded from efficacy
                  analysis but kept in the safety analysis.

        Exclusion Criteria:

          1. COPD or asthma on active bronchodilator therapy

          2. Active treatment with beta blockers

          3. Left bundle branch block or pacemaker.

          4. Systolic blood pressure &lt;120 mmHg, Heart rate &lt;60 bpm, or AV block (PR˃240 mS or
             superior) on diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Borja Ibanez, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CNIC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Vigo-Hospital Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Urgencias Sanitarias 061 de Galicia</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <zip>24008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Asistencia Municipal de Urgencia y Rescate (SAMUR)</name>
      <address>
        <city>Madrid</city>
        <zip>28011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>• Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC),</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Urgencia Médica de la Comunidad de Madrid (SUMMA) 112</name>
      <address>
        <city>Madrid</city>
        <zip>28045</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirón</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cnic.es</url>
  </link>
  <link>
    <url>https://metocard.cnic.es/</url>
    <description>Official Study Website</description>
  </link>
  <reference>
    <citation>Ibanez B, Prat-González S, Speidl WS, Vilahur G, Pinero A, Cimmino G, García MJ, Fuster V, Sanz J, Badimon JJ. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation. 2007 Jun 12;115(23):2909-16. Epub 2007 May 21.</citation>
    <PMID>17515460</PMID>
  </reference>
  <reference>
    <citation>Ibanez B, Cimmino G, Prat-González S, Vilahur G, Hutter R, García MJ, Fuster V, Sanz J, Badimon L, Badimon JJ. The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion. Int J Cardiol. 2011 Mar 17;147(3):428-32. doi: 10.1016/j.ijcard.2009.09.551. Epub 2009 Nov 12.</citation>
    <PMID>19913314</PMID>
  </reference>
  <reference>
    <citation>Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. Circulation. 2000 Jul 11;102(2):166-72.</citation>
    <PMID>10889126</PMID>
  </reference>
  <reference>
    <citation>Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong E, Lansky AJ, Stone GW. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol. 2004 May 19;43(10):1780-7.</citation>
    <PMID>15145099</PMID>
  </reference>
  <reference>
    <citation>Harjai KJ, Stone GW, Boura J, Grines L, Garcia E, Brodie B, Cox D, O'Neill WW, Grines C. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 2003 Mar 15;91(6):655-60.</citation>
    <PMID>12633793</PMID>
  </reference>
  <reference>
    <citation>Larose E, Rodés-Cabau J, Pibarot P, Rinfret S, Proulx G, Nguyen CM, Déry JP, Gleeton O, Roy L, Noël B, Barbeau G, Rouleau J, Boudreault JR, Amyot M, De Larochellière R, Bertrand OF. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol. 2010 Jun 1;55(22):2459-69. doi: 10.1016/j.jacc.2010.02.033.</citation>
    <PMID>20510213</PMID>
  </reference>
  <reference>
    <citation>Raman SV, Simonetti OP, Winner MW 3rd, Dickerson JA, He X, Mazzaferri EL Jr, Ambrosio G. Cardiac magnetic resonance with edema imaging identifies myocardium at risk and predicts worse outcome in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010 Jun 1;55(22):2480-8. doi: 10.1016/j.jacc.2010.01.047.</citation>
    <PMID>20510215</PMID>
  </reference>
  <reference>
    <citation>Ibanez B, Fuster V, Macaya C, Sánchez-Brunete V, Pizarro G, López-Romero P, Mateos A, Jiménez-Borreguero J, Fernández-Ortiz A, Sanz G, Fernández-Friera L, Corral E, Barreiro MV, Ruiz-Mateos B, Goicolea J, Hernández-Antolín R, Acebal C, García-Rubira JC, Albarrán A, Zamorano JL, Casado I, Valenciano J, Fernández-Vázquez F, de la Torre JM, Pérez de Prado A, Iglesias-Vázquez JA, Martínez-Tenorio P, Iñiguez A. Study design for the &quot;effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion&quot; (METOCARD-CNIC): a randomized, controlled parallel-group, observer-blinded clinical trial of early pre-reperfusion metoprolol administration in ST-segment elevation myocardial infarction. Am Heart J. 2012 Oct;164(4):473-480.e5. doi: 10.1016/j.ahj.2012.07.020.</citation>
    <PMID>23067904</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemia</keyword>
  <keyword>Reperfusion</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Beta blockers</keyword>
  <keyword>Metoprolol</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Necrosis</keyword>
  <keyword>Salvaged Myocardium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

